Juvenile Arthritis News

Anti-ribosomal P autoantibodies had a high specificity for systemic lupus erythematosus, and their measurement might improve disease diagnosis, according to study results.

The FDA has approved Ilaris to treat patients aged 2 years or older with active systemic juvenile idiopathic arthritis, Novartis announced today.

Children and adolescents with rheumatic fever or juvenile arthritis are prone to autoimmune thyroid disorders and would benefit from routine screening, according to recent results.

Researchers from Hospital for Special Surgery have found that total knee replacement improved the long-term quality of life for patients with juvenile idiopathic arthritis, but noted survivorship of the implants were lower than in elderly osteoarthritic patients.

Patients with systemic juvenile idiopathic arthritis were more responsive to tocilizumab therapy than placebo patients but experienced more adverse events, including infection and neutropenia, according to study results.

Children were twice as likely to develop musculoskeletal pain in certain joints when those joints were hypermobile, according to study results in Arthritis Care & Research.

About half of children with juvenile idiopathic arthritis who were treated with etanercept achieved an inactive disease state, according to study results.

The majority of patients with newly diagnosed juvenile idiopathic arthritis achieved an episode of inactive disease within a median of 10 months, according to study results.

Adolescents had varied beliefs about the underlying cause of their juvenile arthritis, with genetics and the immune system being the most common, according to study results.

More than half the children and adolescents with juvenile idiopathic arthritis reported suboptimal health-related quality of life, and their parents indicated even lower scores for their daughters, according to study results.